Restricted stock

Salesforce Grants Equity Awards to Acumen Solutions Employees Under Its Inducement Equity Incentive Plan

Retrieved on: 
금요일, 2월 26, 2021
Cloud applications, Financial markets, Computer companies, Salesforce, Finance, Restricted stock, Acumen

SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Salesforce (NYSE: CRM), the global leader in CRM, today announced it has granted equity awards under its 2014 Inducement Equity Incentive Plan (the "Plan") to new employees who joined Salesforce in connection with the acquisition of Acumen Solutions.

Key Points: 
  • SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Salesforce (NYSE: CRM), the global leader in CRM, today announced it has granted equity awards under its 2014 Inducement Equity Incentive Plan (the "Plan") to new employees who joined Salesforce in connection with the acquisition of Acumen Solutions.
  • Now with Salesforce Industries (formerly Vlocity) and Acumen Solutions, Salesforce can better provide customers across all industries with products and solutions that meet their specific needs.
  • Through the Plan, Acumen employees will receive various equity awards as provided below.
  • Under the Plan, Salesforce granted a total of 177,934 restricted stock units ("RSUs") and 16,602 stock options to 471 Acumen employees.

Synchronoss Technologies, Inc. Reports Inducement Grants to Employees Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
월요일, 2월 22, 2021
Corporate finance, Stock market, Finance, Financial economics, Money, Employee stock ownership, Fundamental analysis, Restricted stock, Executive compensation, Stock

Each of these grants was an inducement award that was approved by the Compensation Committee of Synchronoss Board of Directors, and granted as an inducement equity award under the Company's 2017 New Hire Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • Each of these grants was an inducement award that was approved by the Compensation Committee of Synchronoss Board of Directors, and granted as an inducement equity award under the Company's 2017 New Hire Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Synchronoss granted the three newly hired employees an aggregate of 5,925 time-based restricted stock awards.
  • In addition, the employees received an aggregate of 1,975 time-based stock option awards.
  • Synchronoss secure, scalable and groundbreaking new technologies, trusted partnerships and talented people change the way TMT customers grow their business.

J.Jill, Inc. Announces Inducement Grant Under New York Stock Exchange Rule 303A.08

Retrieved on: 
목요일, 2월 18, 2021
Women, Other Retail, Teens, Online Retail, Consumer, Fashion, Other Consumer, Retail, J.Jill, Finance, Financial markets, Restricted stock, Omnichannel, Spofford, New York Stock Exchange, Money

On February 15, 2021, J.Jill, Inc. (NYSE: JILL) made a grant to Claire Spofford of 300,000 restricted stock units in respect of the companys common stock (RSUs).

Key Points: 
  • On February 15, 2021, J.Jill, Inc. (NYSE: JILL) made a grant to Claire Spofford of 300,000 restricted stock units in respect of the companys common stock (RSUs).
  • The grant of RSUs was offered as a material inducement to Ms. Spoffords hiring as Chief Executive Officer of the company.
  • Ms. Spofford, whose hiring was announced on October 7, 2020, joined the company on February 15, 2021.
  • J.Jill is a premier omnichannel retailer and nationally recognized womens apparel brand committed to delighting customers with great wear-now product.

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

Retrieved on: 
수요일, 2월 17, 2021
Corporate finance, Financial markets, Financial economics, Finance, Stock market, Equity securities, Employee stock ownership, Fundamental analysis, Restricted stock, Stock, Common stock

The equity awards were granted to the employees joining Myovant in accordance with NYSEs Listed Company Manual Rule 303A.08.

Key Points: 
  • The equity awards were granted to the employees joining Myovant in accordance with NYSEs Listed Company Manual Rule 303A.08.
  • The new employees received, in the aggregate, restricted stock units (RSUs) to purchase 30,000 common shares of Myovant.
  • The RSUs are subject to the terms and conditions of the 2020 Inducement Plan and the applicable restricted stock unit agreements.
  • Myovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
화요일, 2월 9, 2021
Biotechnology, General Health, Public relations, Investor relations, Health, Communications, Puma Biotechnology, Puma, Restricted stock, Finance, Financial economics, Clothing

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 4, 2021 the Compensation Committee of Pumas Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 11,000 shares of Puma common stock to two new non-executive employees.

Key Points: 
  • Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 4, 2021 the Compensation Committee of Pumas Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 11,000 shares of Puma common stock to two new non-executive employees.
  • The awards were granted under Pumas 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma.
  • The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.

Pacific Biosciences Grants Equity Incentive Award to New Employee

Retrieved on: 
금요일, 2월 5, 2021
Financial markets, Finance, Financial economics, Corporate finance, Stock market, Pacific Biosciences, Stock, NASDAQ, Restricted stock

MENLO PARK, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (Pacific Biosciences or the Company), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Companys Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock and restricted stock units (RSU) covering 50,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan on December 14, 2020 (the 2020 Inducement Plan).

Key Points: 
  • MENLO PARK, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (Pacific Biosciences or the Company), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Companys Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock and restricted stock units (RSU) covering 50,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan on December 14, 2020 (the 2020 Inducement Plan).
  • The options have an exercise price of $ 34.18 per share, which is equal to the closing price of Pacific Biosciences common stock on February 1, 2021 (the Effective Date).
  • The option grant and the award of restricted stock units are subject to the terms and conditions of the 2020 Inducement Plan and the award agreements entered into with the non-executive officer employee.
  • Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
금요일, 2월 5, 2021
Financial markets, Finance, Corporate finance, Financial economics, Stock market, Options, Equity securities, Fundamental analysis, Restricted stock, Stock, Exercise, NASDAQ

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received options to purchase 56,500 shares of Apellis common stock and 13,275 restricted stock units (RSUs).
  • The options have an exercise price of $44.20, which is equal to the closing price of Apellis common stock on February 1, 2021, the grant date of the options.
  • Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies.

SeaSpine Reports Granting of Inducement Awards

Retrieved on: 
금요일, 2월 5, 2021
Financial markets, Finance, Corporate finance, Financial economics, Stock market, Equity securities, Employee stock ownership, Fundamental analysis, Restricted stock, Stock, NASDAQ, Executive compensation

The awards were made on February 1, 2021 under SeaSpines 2020 Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of SeaSpine.

Key Points: 
  • The awards were made on February 1, 2021 under SeaSpines 2020 Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of SeaSpine.
  • The inducement awards consist of options to purchase 16,533 shares of SeaSpine common stock and restricted stock unit awards with respect to an aggregate of 11,636 shares of SeaSpine common stock.
  • The awards were approved by the independent compensation committee of SeaSpines board of directors and were granted as an inducement material to the new employees entering into employment with SeaSpine in accordance with Nasdaq Marketplace Rule 5635(c)(4).
  • SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
토요일, 1월 30, 2021
Finance, Money, Stock market, Corporate finance, Economy, Employee stock ownership, Fundamental analysis, Restricted stock, Stock, Investor

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 20,565 shares of Sarepta's common stock, and in the aggregate, 7,760 restricted stock units (RSUs).
  • We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com .
  • We encourage investors and potential investors to consult our website regularly for important information about us.

Pacific Biosciences Grants Equity Incentive Award to New Employee

Retrieved on: 
금요일, 1월 29, 2021
Financial markets, Finance, Financial economics, Corporate finance, Stock market, Pacific Biosciences, Stock, NASDAQ, Restricted stock

MENLO PARK, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (Pacific Biosciences or the Company), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Companys Board of Directors granted non-qualified stock options covering an aggregate of 110,000 shares of Pacific Biosciences common stock and restricted stock units (RSU) covering 55,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan on December 14, 2020 (the 2020 Inducement Plan).

Key Points: 
  • MENLO PARK, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (Pacific Biosciences or the Company), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Companys Board of Directors granted non-qualified stock options covering an aggregate of 110,000 shares of Pacific Biosciences common stock and restricted stock units (RSU) covering 55,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan on December 14, 2020 (the 2020 Inducement Plan).
  • The options have an exercise price of $ 35.95 per share, which is equal to the closing price of Pacific Biosciences common stock on January 25, 2021 (the Effective Date).
  • The option grant and the award of restricted stock units are subject to the terms and conditions of the 2020 Inducement Plan and the award agreements entered into with the non-executive officer employee.
  • Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing.